Logo image of FOLD

AMICUS THERAPEUTICS INC (FOLD) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:FOLD - US03152W1099 - Common Stock

14.29 USD
0 (0%)
Last: 1/28/2026, 10:21:59 AM
Fundamental Rating

4

Overall FOLD gets a fundamental rating of 4 out of 10. We evaluated FOLD against 525 industry peers in the Biotechnology industry. FOLD has an average financial health and profitability rating. FOLD has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • FOLD had negative earnings in the past year.
  • In the past year FOLD had a positive cash flow from operations.
  • In the past 5 years FOLD always reported negative net income.
  • In the past 5 years FOLD always reported negative operating cash flow.
FOLD Yearly Net Income VS EBIT VS OCF VS FCFFOLD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

  • FOLD has a Return On Assets of -1.62%. This is amongst the best in the industry. FOLD outperforms 87.81% of its industry peers.
  • Looking at the Return On Equity, with a value of -6.10%, FOLD belongs to the top of the industry, outperforming 88.95% of the companies in the same industry.
  • FOLD's Return On Invested Capital of 4.07% is amongst the best of the industry. FOLD outperforms 91.05% of its industry peers.
Industry RankSector Rank
ROA -1.62%
ROE -6.1%
ROIC 4.07%
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
FOLD Yearly ROA, ROE, ROICFOLD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

  • The Operating Margin of FOLD (5.77%) is better than 89.90% of its industry peers.
  • The Gross Margin of FOLD (89.77%) is better than 92.19% of its industry peers.
  • FOLD's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 5.77%
PM (TTM) N/A
GM 89.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
FOLD Yearly Profit, Operating, Gross MarginsFOLD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

4

2. Health

2.1 Basic Checks

  • FOLD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • FOLD has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, FOLD has more shares outstanding
  • FOLD has a better debt/assets ratio than last year.
FOLD Yearly Shares OutstandingFOLD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
FOLD Yearly Total Debt VS Total AssetsFOLD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of 1.05, we must say that FOLD is in the distress zone and has some risk of bankruptcy.
  • FOLD's Altman-Z score of 1.05 is fine compared to the rest of the industry. FOLD outperforms 63.24% of its industry peers.
  • FOLD has a debt to FCF ratio of 40.45. This is a negative value and a sign of low solvency as FOLD would need 40.45 years to pay back of all of its debts.
  • FOLD has a Debt to FCF ratio of 40.45. This is amongst the best in the industry. FOLD outperforms 89.90% of its industry peers.
  • FOLD has a Debt/Equity ratio of 1.70. This is a high value indicating a heavy dependency on external financing.
  • FOLD's Debt to Equity ratio of 1.70 is on the low side compared to the rest of the industry. FOLD is outperformed by 77.52% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.7
Debt/FCF 40.45
Altman-Z 1.05
ROIC/WACC0.44
WACC9.25%
FOLD Yearly LT Debt VS Equity VS FCFFOLD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 2.99 indicates that FOLD has no problem at all paying its short term obligations.
  • With a Current ratio value of 2.99, FOLD is not doing good in the industry: 64.00% of the companies in the same industry are doing better.
  • FOLD has a Quick Ratio of 2.09. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.
  • FOLD's Quick ratio of 2.09 is on the low side compared to the rest of the industry. FOLD is outperformed by 73.14% of its industry peers.
Industry RankSector Rank
Current Ratio 2.99
Quick Ratio 2.09
FOLD Yearly Current Assets VS Current LiabilitesFOLD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

6

3. Growth

3.1 Past

  • FOLD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 91.18%, which is quite impressive.
  • FOLD shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.28%.
  • The Revenue has been growing by 23.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)91.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%400%
Revenue 1Y (TTM)21.28%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%19.46%

3.2 Future

  • The Earnings Per Share is expected to grow by 69.00% on average over the next years. This is a very strong growth
  • FOLD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.14% yearly.
EPS Next Y89.48%
EPS Next 2Y93.03%
EPS Next 3Y78.09%
EPS Next 5Y69%
Revenue Next Year19.4%
Revenue Next 2Y18.93%
Revenue Next 3Y18.81%
Revenue Next 5Y19.14%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
FOLD Yearly Revenue VS EstimatesFOLD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B
FOLD Yearly EPS VS EstimatesFOLD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1 2 3

5

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for FOLD. In the last year negative earnings were reported.
  • A Price/Forward Earnings ratio of 45.99 indicates a quite expensive valuation of FOLD.
  • 90.67% of the companies in the same industry are more expensive than FOLD, based on the Price/Forward Earnings ratio.
  • FOLD's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 25.95.
Industry RankSector Rank
PE N/A
Fwd PE 45.99
FOLD Price Earnings VS Forward Price EarningsFOLD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200 -300 -400

4.2 Price Multiples

  • FOLD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. FOLD is cheaper than 89.52% of the companies in the same industry.
  • 90.10% of the companies in the same industry are more expensive than FOLD, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 454.95
EV/EBITDA 105.98
FOLD Per share dataFOLD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • FOLD's earnings are expected to grow with 78.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y93.03%
EPS Next 3Y78.09%

0

5. Dividend

5.1 Amount

  • FOLD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

AMICUS THERAPEUTICS INC / FOLD FAQ

What is the fundamental rating for FOLD stock?

ChartMill assigns a fundamental rating of 4 / 10 to FOLD.


What is the valuation status for FOLD stock?

ChartMill assigns a valuation rating of 5 / 10 to AMICUS THERAPEUTICS INC (FOLD). This can be considered as Fairly Valued.


Can you provide the profitability details for AMICUS THERAPEUTICS INC?

AMICUS THERAPEUTICS INC (FOLD) has a profitability rating of 4 / 10.


What is the expected EPS growth for AMICUS THERAPEUTICS INC (FOLD) stock?

The Earnings per Share (EPS) of AMICUS THERAPEUTICS INC (FOLD) is expected to grow by 89.48% in the next year.